Dr. Paul Fernyhough, director of the Division of Neurodegenerative Disorders, in collaboration with researchers at the University of Toronto and University of California (San Diego), has demonstrated a compound that can prevent and reverse sensory neuropathy in diabetic rats and mice; the first step towards a commercial product with a current market of $1.41 billion. Yes, that’s billion.
You will want to read more – Dr. Fernyhough ‘s research has recently been highlighted in “Tomorrow’s Technologies Today”, the University of Manitoba’s Technology Transfer Office newsletter.